

CefTRIAxone Sodium

Brand names Rocephin

Medication error potential ISMP recommends tall man letters (not FDA approved) to decrease confusion between cefTRIAxone and ceFAZolin, cefoTEtan, cefOXitin, and cefTAZidime.⁽¹⁾

Contraindications and warnings **Contraindications:** Should not be used in those with a known allergy to ceftriaxone or another cephalosporin antibiotics.⁽³⁾

Ceftriaxone can displace bilirubin from its binding sites on serum albumin and may cause kernicterus and encephalopathy in hyperbilirubinemic neonates, especially premature neonates.⁽³⁾

Ceftriaxone must not be coadministered with calcium-containing IV solutions (e.g., Ringer's solution, Hartmann's solution, and PN formulations that contain calcium) in neonates because of the risk of precipitation of ceftriaxone–calcium salt.⁽³⁾ Cases of fatal reactions with ceftriaxone–calcium precipitates in lungs and kidneys in neonates have been described.^(3,4) In some cases the infusion lines and the times of administration of ceftriaxone and calcium-containing solutions differed.^(3,4) Ceftriaxone and products that contain calcium may be administered sequentially to patients outside the neonatal period, as long as the infusion lines are thoroughly flushed between infusions with a compatible fluid.⁽³⁾ Ceftriaxone should not be administered simultaneously with any calcium-containing solution via Y-site in any patient.⁽³⁾

Warnings: Individuals who have a type I reaction to penicillin may have cross-sensitivity to cephalosporins. Ceftriaxone should be given cautiously to these patients.⁽³⁾ (See Appendix C for specific information.)

Prolonged use may cause superinfection and/or *Clostridium difficile*-associated diarrhea (CDAD), which has been reported and may range in severity from mild diarrhea to fatal colitis.⁽³⁾

Infusion-related cautions If a decision is made to give this medication to a patient with known penicillin hypersensitivity, the patient should be closely observed for allergenicity. Although rare, anaphylactoid reactions may require immediate emergency treatment with epinephrine and other emergency management.

Dosage **Neonates:** See the Contraindications and Warnings section.⁽⁵⁾

	PNA	≤2000 g	>2000 g
≤7 days		50 mg/kg q 24 hr	50 mg/kg q 24 hr
>7 days		50 mg/kg q 24 hr	50 mg/kg q 24 hr

*Until 4 weeks of age

Infants and children

Non-CNS infection: 50–75 mg/kg/day given as a single dose or divided q 12 hr, up to 2 g/day^(3,5,9,33)

CNS infection: 80–100 mg/kg/day given as a single dose or divided q 12 hr, up to 4 g/day^(3,5,7-13)

Gonococcal infection

Complicated: 50 mg/kg/day (up to 1 g/day) as a single dose for 7 days.^(5,14) If meningitis or endocarditis, give 50 mg/kg/day (up to 2 g/day) divided q 12–24 hr for 10–14 days and 28 days, respectively, plus erythromycin.⁽⁵⁾

Neonatal ophthalmia: 25–50 mg/kg (up to 125 mg) as a single dose IV/IM⁽⁵⁾



CefTRIAxone Sodium

Dosage (cont.)

Prophylaxis: Neonates born to mothers with untreated gonococcal infections should be given 25–50 mg/kg (up to 125 mg) as a one-time dose.^(5,14) If providing prophylaxis after sexual victimization, add appropriate therapies for chlamydia trachomatis, hepatitis B, and trichomoniasis.^(5,14)

Uncomplicated: If ≤45 kg give 25–50 mg/kg/day up to 125 mg, if >45 kg give 250 mg as a single dose IM plus a macrolide antibiotic.^(5,14)

Otitis media: 50 mg/kg (up to 1 g) as a single dose. Generally administered IM.⁽¹⁵⁻¹⁷⁾

Dosage adjustment in organ dysfunction

Most *adult* patients with renal dysfunction who receive ≤2 g/day do not require dosage adjustment.^(3,19) However, some patients with end-stage renal disease receiving hemodialysis may accumulate ceftriaxone.⁽¹⁹⁾ It is recommended that patients with a GFR <10 receive their dose every 24 hours only.⁽¹⁸⁾ No adjustment in hepatic dysfunction; however, if both hepatic and renal dysfunction the dosage should not exceed 2 g/day.⁽³⁾

Maximum dosage 100 mg/kg/day^(3,5) not to exceed 4 g/day^(3,5)

Additives Contains 3.6 mEq sodium/g of ceftriaxone.^(3,20)

Suitable diluents D5NS, D5½NS, D5W, D10W, NS, or SW. Compatibility varies for dextrose-saline combinations. See more specific reference.⁽³⁾

Maximum concentration 40 mg/mL for IV administration and 350 mg/mL for IM use⁽³⁾

Preparation and delivery

Stability: Do not force thaw by immersion in water baths or by microwave irradiation.⁽³⁾ 250 and 350 mg/mL reconstituted solutions are stable for 24 hours at room temperature and for 72 hours if refrigerated.⁽²⁰⁾ 100 mg/mL in SW, NS, or D5W for 48 hours at room temperature and for 10 days if refrigerated.⁽²⁰⁾ Concentrations of 10, 20, and 40 mg/mL remain stable for 2 days at room temperature with suitable diluents. (See the Suitable Diluents section.)⁽³⁾

Compatibility: See Appendix D for PN compatibility information.⁽²¹⁾

Photosensitivity: Protect from light before reconstitution.⁽²⁰⁾

IV push 10–40 mg/mL.^(3,20) Although infusion over 30 minutes is now recommended,⁽³⁾ doses have been given over 2–15 minutes in children.^(10,22) Ten minutes after ceftriaxone was infused over 5 minutes, an *adult* being treated for presumed meningitis became diaphoretic, hypertensive, and tachycardic and developed palpitations.⁽²⁴⁾ Subsequent infusions over 30 minutes were uneventful.⁽²⁴⁾

Intermittent infusion 10–40 mg/mL^(3,20) infused over 30 minutes⁽³⁾

Continuous infusion No specific information is available to support administration by this route.

Other routes of administration 100–350 mg/mL in SW, NS, D5W, BW, or 1% lidocaine (without epinephrine) by deep IM injection^(3,20)

